ORC6 and prostate cancer: In addition, miR-582-3p inhibition affects prostate cancer (PCa) cell function by silencing ORC6 expression [38], and overexpression of miR-582-3p accelerates smooth muscle cell proliferation and promotes carotid artery stenosis progression [39].